Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CC-97489 in Healthy Adults
NCT05099822Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy, Alzheimer's disease (AD) and neurological disorders comparing CC-97489 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events (AEs), Incidence of Serious Adverse Events (SAEs) and 3 more. Started Mar 2020; status: terminated.
02
Drugs
bms-986368
03
Conditions
epilepsyAlzheimer's disease (AD)neurological disorders
Beyond the preview
Go deeper on NCT05099822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099822.